XTX Topco Ltd Invests $1.95 Million in Haemonetics Corporation (NYSE:HAE)

Key Points

• XTX Topco Ltd has acquired a new position in Haemonetics Corporation, purchasing 30,638 shares valued at approximately $1.95 million.
• Haemonetics reported earnings of $1.24 per share for the last quarter, surpassing analyst estimates, but its revenue decreased by 3.5% compared to the previous year.
• The stock currently has a consensus rating of "Moderate Buy" among analysts, with an average price target of $97.30.

XTX Topco Ltd bought a new position in Haemonetics Corporation (NYSE:HAE - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,638 shares of the medical instruments supplier's stock, valued at approximately $1,947,000. XTX Topco Ltd owned about 0.06% of Haemonetics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. Louisiana State Employees Retirement System boosted its position in Haemonetics by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,100 shares of the medical instruments supplier's stock worth $896,000 after purchasing an additional 200 shares during the last quarter. CWC Advisors LLC. boosted its position in Haemonetics by 7.4% in the fourth quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock worth $241,000 after purchasing an additional 212 shares during the last quarter. Vise Technologies Inc. boosted its position in Haemonetics by 8.7% in the fourth quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock worth $221,000 after purchasing an additional 225 shares during the last quarter. HighTower Advisors LLC boosted its position in Haemonetics by 7.8% in the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after purchasing an additional 244 shares during the last quarter. Finally, TD Waterhouse Canada Inc. bought a new position in shares of Haemonetics in the fourth quarter worth about $25,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Price Performance

HAE traded up $0.67 on Friday, hitting $74.71. 490,094 shares of the company's stock traded hands, compared to its average volume of 530,232. The company's 50 day simple moving average is $72.88 and its 200-day simple moving average is $67.67. The firm has a market cap of $3.59 billion, a price-to-earnings ratio of 22.57, a P/E/G ratio of 1.20 and a beta of 0.39. Haemonetics Corporation has a one year low of $55.30 and a one year high of $94.99. The company has a current ratio of 1.62, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.02. The company had revenue of $330.60 million for the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The firm's quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the company earned $0.90 EPS. As a group, research analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on HAE shares. Wall Street Zen downgraded Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $105.00 price objective (down previously from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Citigroup raised Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price objective on the stock in a research note on Wednesday, July 9th. Robert W. Baird started coverage on Haemonetics in a research note on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price objective on the stock. Finally, Baird R W raised Haemonetics to a "strong-buy" rating in a research note on Wednesday, June 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $97.30.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.